205 related articles for article (PubMed ID: 33393719)
21. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
22. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
23. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia.
Cui L; Li Z; Wu M; Li W; Gao C; Deng G
Leuk Res; 2010 Oct; 34(10):1314-9. PubMed ID: 20034668
[TBL] [Abstract][Full Text] [Related]
24. Identifying IGH disease clones for MRD monitoring in childhood B-cell acute lymphoblastic leukemia using RNA-Seq.
Li Z; Jiang N; Lim EH; Chin WHN; Lu Y; Chiew KH; Kham SKY; Yang W; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Leukemia; 2020 Sep; 34(9):2418-2429. PubMed ID: 32099036
[TBL] [Abstract][Full Text] [Related]
25. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection.
Li AH; Rosenquist R; Forestier E; Lindh J; Roos G
Leuk Res; 2001 Dec; 25(12):1033-45. PubMed ID: 11684274
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
27. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
28. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
30. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
[TBL] [Abstract][Full Text] [Related]
31. Combined IKZF1 and IG markers as new tools for diagnosis and minimal residual disease assessment in Tunisian B-ALL.
Besbes S; Hamadou WS; Boulland ML; Lefranc MP; Ben Youssef Y; Achour B; Khelif A; Fest T; Soua Z
Bull Cancer; 2016 Oct; 103(10):822-828. PubMed ID: 27614734
[TBL] [Abstract][Full Text] [Related]
32. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
[TBL] [Abstract][Full Text] [Related]
33. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
34. Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
Zur Stadt U; Alawi M; Adao M; Indenbirken D; Escherich G; Horstmann MA
Blood Cancer J; 2019 Nov; 9(12):96. PubMed ID: 31784504
[TBL] [Abstract][Full Text] [Related]
35. Next-Generation Sequencing for Minimal Residual Disease Surveillance in Acute Lymphoblastic Leukemia: An Update.
Reyes-Barron C; Burack WR; Rothberg PG; Ding Y
Crit Rev Oncog; 2017; 22(5-6):559-567. PubMed ID: 29604931
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit of a high-throughput sequencing approach for minimal residual disease in acute lymphoblastic leukemia.
Wright G; Watt E; Inglott S; Brooks T; Bartram J; Adams SP
Pediatr Blood Cancer; 2019 Aug; 66(8):e27787. PubMed ID: 31034760
[TBL] [Abstract][Full Text] [Related]
37. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
38. [Dynamic monitoring of minimal residual disease in acute lymphoid leukemia].
Shan SL; Xing HY; Tian Z; Tang KJ; Rao Q; Wang M; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1404-8. PubMed ID: 22169292
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia.
Rosenquist R; Thunberg U; Li AH; Forestier E; Lönnerholm G; Lindh J; Sundström C; Sällström J; Holmberg D; Roos G
Eur J Haematol; 1999 Sep; 63(3):171-9. PubMed ID: 10485272
[TBL] [Abstract][Full Text] [Related]
40. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
